Eli Lilly (LLY) announced positive topline results from two phase III studies, QWINT-1 and QWINT-3, which evaluated efsitora alfa, its once-weekly administered investigational insulin, in adults with type II diabetes (T2D).LLY’s Weekly Insulin Shot Matches Daily InsulinThe QWINT-1 study compared efsitora to daily injections of Sanofi’s (SNY) Lantus (insulin glargine) for 52 weeks in T2D patients using basal insulin for the first time. The QWINT-3 study compared efsitora with daily shots of Novo Nordisk’s (N ...